Benitec Biopharma
BNTC
Market cap $433M

16.48 USD

+0.56

3.52%

At close Jun 13, 4:00 PM EDT

After hours

16.48

+0.00

0.00%

1 day

3.52%

5 days

0.55%

1 month

25.04%

3 months

11.35%

6 months

40.02%

Year to date

36.42%

1 year

120.32%

5 years

-88.00%

10 years

-87.84%

About: Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Employees: 16

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

50% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]

23% more funds holding

Funds holding: 30 [Q4 2024] → 37 (+7) [Q1 2025]

21% more capital invested

Capital invested by funds: $240M [Q4 2024] → $290M (+$50M) [Q1 2025]

4.07% more ownership

Funds ownership: 81.82% [Q4 2024] → 85.89% (+4.07%) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

9%

upside

Avg. target

$22

33%

upside

High target

$28

70%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju	70%upside $28	Buy Reiterated	19 May 2025
JMP Securities Silvan Tuerkcan	21%upside $20	Market Outperform Reiterated	15 May 2025
Citizens Capital Markets Silvan Tuerkcan	9%upside $18	Market Outperform Reiterated	18 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about BNTC published over the past 30 days

Zacks Investment Research

Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 66% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?

Zacks Investment Research

Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year?

Here is how Benitec Biopharma Limited (BNTC) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.

Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year?

Zacks Investment Research

Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why

Zacks Investment Research

Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet

The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 83.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet

Zacks Investment Research

Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?

Zacks Investment Research

Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks Investment Research

Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade

The consensus price target hints at an 85% upside potential for Benitec Biopharma (BNTC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade

Zacks Investment Research

What Makes Benitec Biopharma (BNTC) a New Buy Stock

Benitec Biopharma (BNTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Benitec Biopharma (BNTC) a New Buy Stock

Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer

We initiate a Buy rating for Benitec Biopharma due to promising early data from BB 301 for OPMD and a cash runway into mid-2027. BB 301 shows potential for meaningful improvements in swallowing function, with significant commercial opportunities and an undervalued stock price reflecting high-dose cohort data. Financially, Benitec has no revenue, rising operating expenses, and a cash balance of $78.3 million, providing a runway into mid-2027, though burn rate may increase.

Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer

See News Rankings

Charts implemented using Lightweight Charts™